Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.

CNS Drugs · 2018 · PMC6280853 · PMID 30267385

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a strong trendp = 0.06so close (0.05 < p ≤ 0.1)

However, there was a strong trend for improvement with opicinumab over 32 weeks; the mean gain versus placebo was 22.32 nV (95% CI − 1.26 to 45.89; p = 0.06; Fig. 3 a; MMRM; ITT population).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.